{"nctId":"NCT01303406","briefTitle":"Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)","startDateStruct":{"date":"2011-04"},"conditions":["Friedreich's Ataxia"],"count":29,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"idebenone","type":"EXPERIMENTAL","interventionNames":["Drug: Idebenone"]}],"interventions":[{"name":"Idebenone","otherNames":["Catena (approved name in Canada)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of V5 (Month 12), V6 (Month 18), or V7 (Month 24) in the MICONOS extension study\n* Patients who in the opinion of the investigator are able to comply with the requirements of the study\n* Body weight â‰¥ 25kg\n* Negative urine pregnancy test\n\nExclusion Criteria:\n\n* AE during the course of the MICONOS extension study which in the opinion of the investigator is attributable to idebenone and precludes further treatment with idebenone\n* Clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal SGOT, SGPT or creatinine\n* Parallel participation in another clinical drug trial\n* Pregnancy or breast-feeding\n* Abuse of drugs or alcohol\n* Any change of concomitant medication within the last 30 days that in the opinion of the investigator the intake could negatively impact the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Assessment of Treatment Assignment: Comparison of the Proportions of Patients Randomised to Idebenone and Placebo Who Assessed That They Received Idebenone","description":"The primary efficacy endpoint was the comparison of the number of patients randomized to idebenone and placebo, who assessed that they received idebenone treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Percentage of Participants Randomised to Idebenone and Placebo Who Withdrew Early Due to Recurrence or Worsening of FRDA Symptoms","description":"There was no Withdrawal due to recurrence or worsening of FRDA symptoms","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Fall","Speech disorder","Fatigue","Diarrhea","Pain"]}}}